SOLESENCE, INC. — Director's Dealing 2021

Nov 30, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2021-11-26

Reporting Person: Cureton Kevin (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-26	Common Stock	M	12607	$0.52	Acquired	38257	Direct
2021-11-26	Common Stock	S	12607	$3.50	Disposed	25650	Direct
2021-11-30	Common Stock	M	24000	$0.415	Acquired	49650	Direct
2021-11-30	Common Stock	M	25000	$0.52	Acquired	74650	Direct
2021-11-30	Common Stock	S	23829	$3.79	Disposed	50821	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-30	Common Stock (right to purchase)	$0.415	M	24000	Disposed	2023-02-14	Common Stock (24000)	Direct
2021-11-26	Common Stock	$0.52	M	12607	Disposed	2023-02-14	Common Stock (12607)	Direct
2021-11-30	Common Stock (right to purchase)	$0.52	M	25000	Disposed	2024-02-13	Common Stock (50000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Common Stock (right to purchase)	$0.44	2025-02-18	Common Stock (50000)	50000	Direct
Common Stock (right to purchase)	$0.42	2026-02-23	Common Stock (43500)	43500	Direct
Common Stock (right to purchase)	$0.68	2027-02-21	Common Stock (50000)	50000	Direct
Common Stock (right to purchase)	$0.82	2028-05-23	Common Stock (80000)	80000	Direct
Common Stock (right to purchase)	$0.51	2029-05-22	Common Stock (16500)	16500	Direct
Common Stock (right to purchase)	$0.45	2027-06-18	Common Stock (90000)	90000	Direct

Footnotes

F1: Following recently reported exercises of 11,668 (11/22/21) and 12,332 (11/24/21) shares, this line item represents the 3rd exercise, of 24,000 shares of the total initial grant of 48,000 shares, leaving a balance of 0 shares remaining relating to this grant.

F2: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

F3: Following the recently reported exercise of 12,393 shares (11/24/21), this line item represents the 2nd exercise, of 12,607 shares of a total initial grant of 75,000 shares, leaving a balance of 50,000 shares remaining relating to this grant, prior to the 11/30/21 exercise reported below.

F4: Following the recently reported exercise of 12,393 shares (11/24/21), and the 2nd exercise of 12,607 shares (11/26/21, reported above) this line item represents the 3rd exercise, of 25,000 shares of the total initial grant of 75,000 shares, leaving a balance of 25,000 shares remaining relating to this grant.